Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

Fundraising for AI-Driven Cell Modeling Surges

August 12, 2025

Biotech startup Tahoe Therapeutics raised $30 million to develop AI models of living human cells, contributing to efforts to sequence over a billion cells for drug discovery applications. Despite...

FDA Approves Boehringer’s Oral Lung Cancer Drug Hernexeos

August 12, 2025

Boehringer Ingelheim received accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted therapy authorized for patients with non-small-cell lung cancer harboring HER2...

Vinay Prasad Returns as FDA CBER Director Amidst Industry Reactions

August 12, 2025

Vinay Prasad was reinstated as director of the FDA’s Center for Biologics Evaluation and Research (CBER) just two weeks after an ouster influenced by political pressure. The FDA commissioner...

Breakthrough in Mitochondria-Targeted Neurodegeneration Therapy

August 12, 2025

Researchers at Inserm and Université de Bordeaux developed mitoDREADD-Gs, a designer receptor targeting mitochondria to enhance energy production and reverse cognitive impairments in Alzheimer’s...

Boston Life Sciences Market Faces Historic Vacancy Amid Funding Slump

August 12, 2025

The Boston metro area’s life sciences real estate market has reached unprecedented vacancy rates, with 17 million square feet of available lab and office space and a 29.7% overall availability...

FDA Accelerates First Oral HER2 Therapy in Lung Cancer

August 12, 2025

Boehringer Ingelheim secured accelerated FDA approval for Hernexeos (zongertinib), the first oral HER2-targeted treatment for advanced non-small cell lung cancer (NSCLC) harboring activating HER2...

IO Biotech’s Melanoma Vaccine Misses Endpoint Narrowly, Eyes FDA Submission

August 12, 2025

IO Biotech’s off-the-shelf therapeutic cancer vaccine, Cylembio, narrowly missed statistical significance in its Phase 3 melanoma trial when combined with Merck's Keytruda, despite showing a 23%...

Novartis Scores Dual Phase 3 Wins in Sjögren’s Syndrome Trials

August 12, 2025

Novartis announced successful Phase 3 trial outcomes for ianalumab, a B-cell targeting antibody showing statistically significant improvements in disease activity for Sjögren’s syndrome patients....

Vaxart’s Covid Vaccine Trial Faces Second Stop-Work Order Amid Uncertainties

August 12, 2025

Vaxart received another stop work order for its federally funded oral Covid-19 vaccine Phase 2b trial managed by Advanced Technology International, halting most trial activities despite ongoing...

AI Advances Early Detection of Voice Box Cancer via Acoustic Analysis

August 12, 2025

Researchers have developed AI models capable of distinguishing laryngeal cancer from benign vocal cord lesions through detailed acoustic feature analysis of voice recordings. Utilizing datasets...

Prime Editing Extends Genome Editing Capabilities Beyond Point Mutations

August 12, 2025

David Liu’s team at Harvard has advanced genome editing with twin prime editing, expanding the editing length capacity to 100 base pairs and improving safety over traditional CRISPR approaches....

Mitochondria-Targeted Receptor Restores Cognition in Neurodegenerative Models

August 12, 2025

A novel designer receptor, mitoDREADD-Gs, engineered to activate stimulatory G-protein signaling within brain mitochondria, has been shown to reverse cognitive impairments in mouse models of...

Breastmilk IgA Antibodies Modulate Infant Gut Microbiota and Allergy Risks

August 12, 2025

Researchers from the University of British Columbia revealed that IgA antibodies in breastmilk specifically inhibit the gut bacterium Erysipelatoclostridium ramosum, which is implicated in...

Biotech Funding Slows: Standard BioTools Revenues Fall Amid Transformation

August 12, 2025

Standard BioTools reported a 3% year-over-year revenue decline in Q2 2025, with notable decreases in instrument and service sales offset somewhat by consumables growth. The company’s net loss...

Sartorius and Nanotein Partner to Enhance Immune Cell Therapy Production

August 12, 2025

Sartorius Stedim Biotech announced a partnership and minority investment in Nanotein Technologies to commercialize NanoSpark® platform products aimed at improving T cell and natural killer cell...

AI Breakthroughs in Cancer and Voice Box Diagnostics

August 12, 2025

Recent advances showcase the growing role of artificial intelligence in cancer detection and treatment research. Tahoe Therapeutics raised $30 million aiming to build AI models of living human...

Next-Generation Genome Editing: Prime Editing Expands CRISPR Applications

August 12, 2025

Prime editing emerges as a versatile and safer alternative to traditional CRISPR technology, enabling precise genome modifications without double-stranded DNA breaks. Biochemist David Liu's...

Mitochondrial Therapeutics Reverse Neurodegeneration in Animal Models

August 12, 2025

Targeting mitochondrial dysfunction presents a promising strategy for neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. Researchers developed mitoDREADD-Gs, a...

Novartis Scores in Sjögren’s Syndrome with Dual-Mechanism Antibody

August 12, 2025

Novartis reported successful phase 3 trial results for ianalumab, an antibody targeting BAFF-R, in patients with Sjögren’s syndrome. The drug demonstrated statistically significant reductions in...

IO Biotech’s Cancer Vaccine Misses Endpoint but Eyes FDA Filing

August 12, 2025

IO Biotech's off-the-shelf therapeutic cancer vaccine Cylembio narrowly failed to demonstrate statistical significance for progression-free survival when combined with Keytruda in unresectable or...